TICKERNERD
Menu
ARCTARCTHealthcare · Biotechnology

ARCT Stock Forecast: Arcturus Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$14
+6.62% on the day

The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. hold a median 12-month price target of $20 — +39.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$382.3M
Ticker Nerd rank
61 / 100
Median analyst target
$20
Analysts covering
13
Total return, dividends reinvested
1W
+76.2%
1M
+159.3%
YTD
+133.9%
1Y
−22.5%
From 52W high
−38.1%
From 52W low
+159.3%
$6
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arcturus Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
79
Accruals
75
Issuance
70
Value
65
Quality
63
Size
57
Volatility
26
Momentum
21
Growth
19

Revisions (79): Analysts have, on balance, been raising their forecasts.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26ARCTHigh $40Median $20Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
10 Buy3 Hold0 Sell
Low $8Median $20High $40

The green dot is the last close — the median target sits +39.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 July 2026Freedom BrokerInitiatesBuy$27
18 Mar 2026B. Riley SecuritiesInitiatesBuy—
5 Mar 2026CitigroupMaintainsBuy—
4 Mar 2026CitigroupMaintainsNeutral—
4 Mar 2026Piper SandlerMaintainsOverweight—
6 Jan 2026CitigroupMaintainsNeutral—
13 Nov 2025CitigroupMaintainsNeutral—
11 Nov 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2025Piper SandlerMaintainsOverweight—
24 Oct 2025HC Wainwright & Co.DowngradeNeutral—
23 Oct 2025CitigroupDowngradeNeutral—
23 Oct 2025GuggenheimDowngradeNeutral—
23 Oct 2025Wells FargoMaintainsOverweight—
22 Oct 2025BTIGMaintainsBuy—
22 Oct 2025GuggenheimDowngradeNeutral—
4 Sept 2025HC Wainwright & Co.AssumesBuy$60
22 Aug 2025Leerink PartnersMaintainsOutperform—
12 Aug 2025CitigroupMaintainsBuy—
12 Aug 2025Wells FargoMaintainsOverweight—
2 July 2025ScotiabankMaintainsSector Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
5
Fundamentals

Arcturus Therapeutics Holdings, Inc. (ARCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.1×

Cheaper than 59% of US stocks

Price / sales
13.0×

Cheaper than 13% of US stocks

Price / book
2.2×

Cheaper than 44% of US stocks

EV / EBITDA
−2.1×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−89.5%

Higher than 2% of US stocks

Earnings growth (YoY)
−96.4%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−863.3%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.3%

Higher than 22% of US stocks

Return on assets
−24.0%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARCTArcturus Therapeutics Holdings, Inc.$382.3M
61
UPBUpstream Bio, Inc.$381.8M
31
LXEOLexeo Therapeutics, Inc.$383.2M
31
LYELLyell Immunopharma, Inc.$380.6M
65
RCKTRocket Pharmaceuticals, Inc.$379.9M
52
ENTAEnanta Pharmaceuticals, Inc.$388.6M
87
IPSCCentury Therapeutics, Inc.$371.9M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arcturus Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARCT news & analysis

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

MarketBeat · 12 Aug 2026neutral

Arcturus Therapeutics CEO Joseph Payne discussed the company's mRNA platform, which is centered on two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, during a Canaccord discussion. The vaccine business is intended to support the funding of therapeutic development.

Why it matters — An ARCT watcher would care because the CEO laid out the company's strategic direction, highlighting its rare-disease pipeline and how its vaccine revenue is meant to finance therapeutic programs.

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Arcturus Therapeutics Holdings Inc. held its second-quarter 2026 earnings call, and Seeking Alpha published the full transcript of the proceedings. The transcript covers management's discussion of the company's quarterly results and outlook.

Why it matters — A shareholder monitoring ARCT would want to read the transcript for detail on the company's most recent financial performance and strategic commentary.

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Arcturus Therapeutics reported a second-quarter loss of $0.84 per share, which was narrower than the Zacks Consensus Estimate of a $1.07 loss but wider than the $0.34 per-share loss recorded a year earlier.

Why it matters — The company beat analyst revenue expectations and delivered a smaller-than-expected quarterly loss, which ARCT watchers would note as a relative improvement versus consensus.

Arcturus Therapeutics Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Arcturus Therapeutics reported progress across its rare-disease pipeline in its Q2 2026 earnings call, including completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study. The company also regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.

Why it matters — ARCT watchers would track these developments because pipeline advancement and the regaining of global rights to the KOSTAIVE vaccine and mRNA platform could affect the company's strategic direction and product prospects.

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Business Wire · 6 Aug 2026positive

Arcturus Therapeutics announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. The company reported continued progress in its ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across US sites.

Why it matters — The update confirms active enrollment progress in a key Phase 2 cystic fibrosis trial for one of Arcturus' lead pipeline candidates, offering insight into the company's development momentum.

FAQ

Frequently asked questions about ARCT stock

What is the ARCT stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $8 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARCT stock a buy right now?

Of the 13 analysts covering Arcturus Therapeutics Holdings, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcturus Therapeutics Holdings, Inc. 61 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARCT?

As at 22 Aug 2026, Arcturus Therapeutics Holdings, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).

Will ARCT stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +39.5% from the last close, and Ticker Nerd's factor model ranks Arcturus Therapeutics Holdings, Inc. 61 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARCT stock forecast for 2030?

No analyst covering Arcturus Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $40 over the next 12 months.

How has ARCT stock performed over the past year?

Arcturus Therapeutics Holdings, Inc. returned -22.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arcturus Therapeutics Holdings, Inc. do?

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines.

What is the latest news on ARCT?

The most recent item we track (MarketBeat, 12 Aug 2026): "Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline". Arcturus Therapeutics CEO Joseph Payne discussed the company's mRNA platform, which is centered on two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, during a Canaccord discussion. The vaccine business is intended to support the funding of therapeutic development.

Company

About Arcturus Therapeutics Holdings, Inc.

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines. It leverages proprietary LUNAR lipid-mediated delivery and STARR self-amplifying mRNA platforms to advance its pipeline. Key internal programs include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032, an inhaled mRNA therapy for cystic fibrosis, both in Phase 2 clinical studies targeting severe patient populations. In vaccines, it partners with CSL Seqirus on mRNA candidates for COVID-19, influenza, and other infectious diseases, with KOSTAIVE approved in Japan, the EU, and the UK, generating initial commercial sales through collaborators like Meiji and CSL Seqirus. The company operates in a single business segment encompassing discovery, development, and commercialization of mRNA medicines. Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a significant role in the biotech sector by pioneering mRNA technologies for rare diseases and partnered vaccine franchises.

CEO Mr. Joseph E. Payne M.Sc. · 106 employees · United States · https://arcturusrx.com